

### Book Reviews

**Progress in Cancer Research and Therapy, Vol. 5—Cancer Invasion and Metastasis: Biological Mechanisms and Therapy.** Eds. S. B. DAY, W. P. LAIRD MYERS, P. STANSLY, S. GARATTINI, M. G. LEWIS. (1977) New York: Raven Press. 540 pp. U.S. \$42.00 net.

This book represents the proceedings of an international disciplinary workshop sponsored by the Sloan Kettering Memorial Cancer Centre, the NCI Bethesda and Mario Negri Institute for Pharmacological Research in Milan, that took place in December, 1976.

The book is divided into sections which look at basic factors in cellular invasion, the process of metastatic spread, the establishment and distribution of metastasis, immunological aspects and tumour immunity, and, finally, the treatment and prevention of metastatic disease. It is perhaps unfortunate that none of the meeting's discussion is included in the text, although for some sections there is a summary of the discussion by one or other of the participants. Many of the proffered papers, in fact, were reviews of published work but some data from newer model systems either *in vitro* or *in vivo* were also presented.

Overall, this collection of papers represents a good cross-section of work presently in progress in the field of metastasis, both experimentally and clinically.

The introductory chapter "On the Nature of Metastasis" is neither authoritative nor constructive in the context of these proceedings. It is unfortunate that Dr. Day included his own introduction in these proceedings, because it appears to have been based on semantic and quasi-philosophical ideas which in no way set the scene for the ensuing scientific presentations.

These small criticisms apart, this book can be recommended for all scientists and clinicians interested in metastasis as a phenomenon of malignancy.

H. BUSH

**Recent Advances in Cancer Treatment, Vol. 3.** Eds. H. J. TAGNON and M. J.

STAQUET. (1977) New York: Raven Press, EORTC. 360 pp. U.S. \$26.00 net.

This volume is based on a symposium held in Brussels in September 1976 in honour of Henri J. Tagnon. Its extensive international cast dealt with individual tumour topics, some from the point of view of chemotherapy alone, others from the point of view of general clinical management, and whilst it makes no claims to comprehensiveness, the papers deal with some of the most pressing current problems. In addition, there are a number of review papers dealing with cancer therapy in a more general sense, with discussion of some of the more controversial issues. The arrangement of the papers does not appear to have followed any specific pattern but there is much here of interest. It is a book to be dipped into to obtain individual workers' specific viewpoints on important topics rather than a broad review of the current scene.

K. D. BAGSHAWE

**Evans' Histological Appearances of Tumours, 3rd Edition** D. J. B. ASHLEY. (1978) Edinburgh: Churchill Livingstone 857 pp. £40.00 net.

Dr. Winston Evans' well-known "Histological Appearances of Tumours" first appeared in 1956. It was immediately recognised as an indispensable bench book for the practising and trainee histopathologist, and it has maintained that position ever since. A second edition appeared in 1966, but following Dr. Winston Evans' untimely death one had sadly assumed that no further edition would appear. It was therefore welcome news that Dr. Ashley had undertaken a third edition—if for no better reason than the impending disintegration, from constant use, of one's copy of the second.

It is no easy task to update the work of another author, particularly where the book reflects the original author's individual approach as strongly as this book. This was always more than an atlas of tumour histopathology—Winston Evans was no mere morphologist, and his book was concerned

Comparing Treatment Trends for Colorectal Cancer in Clinical Database and Cancer Registry Data: Implications for Monitoring Cancer Care. Ashu Sehgal & Elizabeth A. Davies - 2011 - *Journal of Evaluation in Clinical Practice* 17 (3):486-492. Explaining Inequalities in Access to Treatment in Lung Cancer. Ruth H. Jack, Martin C. Gulliford, Jamie Ferguson & Henrik MÅller - 2006 - *Journal of Evaluation in Clinical Practice* 12 (5):573-582. Is the Treatment Beneficial, Experimental, or Futile?Å Cancer Disclosure From Recent Medical Malpractice Cases in Japan. Sumiko Takanami - 2002 - *Eubios Journal of Asian and International Bioethics* 12 (1):19-20. Analytics. Added to PP index 2015-09-03. Total views 4 ( #1,151,791 of 2,295,261 ). Recent downloads (6 months) 1 ( #795,703 of 2,295,261 ). colorectal cancer, and hematologic malignancies, which emphasizes the value of targeting this pathway as a potential therapeutic direction in the treatment of cancer [7]. Inhibition of PI3K can result in both decreased cellular proliferation and increased cellular death [8]. Small molecule inhibitors of PI3K include PI3K/mTOR inhibitors, pan-PI3K inhibitors, and isoform-selective.Å For example, PI3K delta-specific inhibitor idelalisib is the first PI3Ki compound approved by United States Food and Drug Administration (FDA) and is proved to be effective in the cancer treatment [9]. In this review, we summarized the role of the PI3K signaling in tumor progression, recent PI3K inhibitors development based on clinical trials, and. In: *Recent advances in cancer treatment*, Vol. 3. Tagnon, H. J., Staquet, M. J. (eds.), p. 227. New York: Raven Press 1977Google Scholar. Copyright information.Å In: Henningsen B., Linder F., Steichele C. (eds) *Endocrine Treatment of Breast Cancer. Recent Results in Cancer Research / Fortschritte der Krebsforschung / ProgrÅs dans les recherches sur le cancer*, vol 71. Springer, Berlin, Heidelberg. DOI [https://doi.org/10.1007/978-3-642-81406-8\\_23](https://doi.org/10.1007/978-3-642-81406-8_23).